Results 51 to 60 of about 3,000 (187)
BackgroundRapid new diagnostic methods (including Xpert MTB/RIF assay) use rifampicin resistance as a surrogate marker for multidrug resistant tuberculosis. Patients infected with rifampicin susceptible strains are prescribed first line anti-tuberculosis
Naima Fasih +3 more
doaj +1 more source
Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem +5 more
wiley +1 more source
Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba +2 more
wiley +1 more source
Plasmid-mediated rifampicin resistance in Pseudomonas fluorescens [PDF]
Rifampicin is an antibiotic mostly used to treat tuberculosis and leprosy, and, occasionally, other diseases. Resistance is due to alterations in membrane permeability or to mutation in the rpoB gene coding for mRNA polymerase. Both these mechanisms originate via chromosomal mutation.
S, Chandrasekaran, D, Lalithakumari
openaire +2 more sources
Dicloxacillin is a penicillinase‐resistant beta‐lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin‐treated patients and increases the risk of thromboembolic events.
Chanan Shaul +5 more
wiley +1 more source
Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. [PDF]
BACKGROUND:Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance on
Leonela Villegas +6 more
doaj +1 more source
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer +9 more
wiley +1 more source
Corallopyronin A (CorA) is a natural RNA polymerase (RNAP) inhibitor active against Gram-positive pathogens, including Staphylococcus aureus. Although spontaneous resistance to CorA occurs less frequently than to rifampicin, the genetic basis and ...
Jesenko Karačić +7 more
doaj +1 more source
Abstract Rhodococcus equi is a facultative intracellular pathogen and a major cause of pneumonia in foals worldwide. The standard treatment for affected foals is a combination of a macrolide with rifampicin. The widespread use of this combination has led to the emergence of multidrug‐resistant (MDR) strains of R. equi.
Marlane Geribone Seeger +7 more
wiley +1 more source
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source

